Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$520,000 |
 |
Gilead SciencesGILD |
-$2B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$109M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Alfieri Michael | Aug 13, 2025 | Buy | 2,500 | $5.3 | $13,000 |
| Machatha Stephen | Aug 11, 2025 | Sell | 22,073 | $5.1517 | $110,000 |
| EDELMAN JOSEPH | Apr 3, 2025 | Sell | 3,400,000 | $1.42 | $4.8M |
| Machatha Stephen | Aug 12, 2024 | Sell | 16,041 | $4.7363 | $76,000 |
| Greenberg Bruce | Aug 12, 2024 | Sell | 10,834 | $4.7363 | $51,000 |
| EDELMAN JOSEPH | Apr 5, 2024 | Buy | 37,712 | $4.74 | $180,000 |
| EDELMAN JOSEPH | Apr 4, 2024 | Buy | 140,281 | $4.67 | $660,000 |
| EDELMAN JOSEPH | Apr 3, 2024 | Buy | 309,847 | $4.09 | $1.3M |
| EDELMAN JOSEPH | Apr 2, 2024 | Buy | 186,051 | $3.44 | $640,000 |
| EDELMAN JOSEPH | Apr 1, 2024 | Buy | 8,374 | $3.25 | $27,000 |
| Machatha Stephen | Mar 12, 2024 | Sell | 11,537 | $3.164 | $37,000 |
| Machatha Stephen | Mar 12, 2024 | Sell | 11,537 | $3.164 | $37,000 |
| Brady Todd C | Mar 12, 2024 | Sell | 85,324 | $3.05 | $260,000 |
| Greenberg Bruce | Mar 11, 2024 | Sell | 13,201 | $3.4064 | $45,000 |
| Greenberg Bruce | Mar 11, 2024 | Sell | 13,201 | $3.4064 | $45,000 |
| Machatha Stephen | Mar 11, 2024 | Sell | 18,231 | $3.4064 | $62,000 |
| Brady Todd C | Mar 11, 2024 | Sell | 97,914 | $3.2735 | $320,000 |
FAQ - Insider Transactions
The most recent insider transaction for Aldeyra Therapeutics was conducted by Alfieri Michael, who sold 2,500 shares on August 13, 2025 at a price of $5.30 per share.
EDELMAN JOSEPH has bought the most ALDX stock in the last 2 years, with a total value of $2.8M.
EDELMAN JOSEPH has sold the most ALDX stock in the last 2 years, with a total value of $4.8M.
The total value of insider transactions for Aldeyra Therapeutics in the last 2 years is negative, amounting to -$3.1M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Aldeyra Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
